COX-2-PGE₂-EPs in gynecological cancers

Area of Science:

• Gynecological Oncology
• Inflammation Research
• Chemoprevention

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXibs) demonstrate inhibitory effects on endometrial, ovarian, and cervical cancers.
• Adverse effects of NSAIDs and COXibs necessitate exploration of novel, specific anti-inflammatory targets for chemoprevention.
• The cyclooxygenase 2-prostaglandin E2-prostaglandin E2 receptors (COX-2-PGE2-EPs) signaling pathway is central to gynecological carcinogenesis.

Purpose of the Study:

• To review the role of the COX-2-PGE2-EPs signaling pathway in gynecological malignancies.
• To identify potential novel therapeutic targets for gynecological cancer chemoprevention.

Main Methods:

• Comprehensive literature searches were conducted.
• Focus on the function of COX-2-PGE2-EPs in endometrial, ovarian, and cervical cancers.

Main Results:

• Upregulated expression of the COX-2-PGE2-EPs pathway is observed in gynecological malignancies.
• COX-2 and cAMP-linked EP2/EP4 and EP3 signaling pathways are implicated in gynecological cancers.
• The roles of EP1 and precise pathological mechanisms require further clarification.

Conclusions:

• Prostaglandin E2 receptors (EPs) are promising anti-inflammatory biomarkers for gynecological cancer.
• EPs represent potential novel therapeutic targets for future gynecological cancer treatment.
• Combining COX enzyme inhibitors with EP receptor antagonists may offer therapeutic advantages.